1-[4-(苯基甲氧基)苯基]-2-[4-(苯基甲基)哌啶-1-基]丙-1-酮 | 35133-39-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 中文名称: 1-[4-(苯基甲氧基)苯基]-2-[4-(苯基甲基)哌啶-1-基]丙-1-酮
• 英文名称: 1-(4-(benzyloxy)phenyl)-2-(4-benzylpiperidin-1-yl)propan-1-one
• 英文别名: 1-(4-benzyloxy-phenyl)-2-(4-benzyl-piperidin-1-yl)-propan-1-one；1-[4-(phenylmethoxy)phenyl]-2-[4-(phenylmethyl)piperidino]propan-1-one；2-(4-benzylpiperidino)-4'-benzyloxypropiophenone；2-(4-benzylpiperidin-1-yl)-1-(4-phenylmethoxyphenyl)propan-1-one
• CAS: 35133-39-2
• 化学式: C₂₈H₃₁NO₂
• 分子量: 413.56
• InChiKey: JKJGWNLFPHYECD-UHFFFAOYSA-N

物化性质

• 熔点：
  85-86 °C(Solv: ethanol (64-17-5))
• 沸点：
  569.6±35.0 °C(Predicted)
• 密度：
  1.111±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  6.2
• 重原子数：
  31
• 可旋转键数：
  8
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.32
• 拓扑面积：
  29.5
• 氢给体数：
  0
• 氢受体数：
  3

安全信息

• 海关编码：
  2933399090

反应信息

• 作为反应物：
  描述：

  1-[4-(苯基甲氧基)苯基]-2-[4-(苯基甲基)哌啶-1-基]丙-1-酮 在 palladium on activated charcoal 钾硼氢 、 氢气 、 溶剂黄146 作用下， 以 甲醇 、 乙醇 为溶剂， 生成 ifenprodil
  参考文献：
  名称：

  Separation of .alpha.1-adrenergic and N-methyl-D-aspartate antagonist activity in a series of ifenprodil compounds

  摘要：

  Ifenprodil (1) represents a new class of N-methyl-D-aspartate (NMDA) antagonist. This drug also possesses potent activity at several other brain receptors (most notably alpha-1 adrenergic receptors). We have prepared the enantiomers and diastereomers of ifenprodil along with a series of partial structures in order to explore the basic structure activity relations within this class of compounds. From this study, it is clear that alpha-1 adrenergic and NMDA receptor activities may be separated by selection of the threo relative stereochemistry. Examination of the optical isomers of threo-ifenprodil (2) reveals that no further improvement in receptor selectivity is gained from either antipode. Individual removal of most of the structural fragments from the ifenprodil molecule generally results in less active compounds although fluorinated derivative 9 with threo relative stereochemistry is somewhat more potent and substantially more selective for the NMDA receptor. Finally a minimum structure for activity in this series (14) has been identified. This stripped-down version of ifenprodil possesses nearly equivalent affinity for the NMDA receptor with no selectivity over alpha-1 adrenergic receptors.

  DOI：

  10.1021/jm00114a018
• 作为产物：
  描述：

  4‘-苄氧基苯丙酮 在 溴 作用下， 以 乙醚 、 乙醇 为溶剂， 反应 0.5h， 生成 1-[4-(苯基甲氧基)苯基]-2-[4-(苯基甲基)哌啶-1-基]丙-1-酮
  参考文献：
  名称：

  Wavelength-dependent optoacoustic imaging probes for NMDA receptor visualisation

  摘要：

  两种针对NMDAR的近红外成像探针的细胞定位和结合特异性已通过显微镜检查，随后通过多光子光声成像技术（MSOT）的示范来监测细胞内模拟谷氨酸突发，并在小鼠中进行了初步研究，观察大脑中的信号。

  DOI：

  10.1039/c5cc06277b

文献信息

• NIS-Catalyzed Reactions: Amidation of Acetophenones and Oxidative Amination of Propiophenones
  作者：Manjunath Lamani、Kandikere Ramaiah Prabhu

  DOI：10.1002/chem.201202703

  日期：2012.11.12

  Single‐step amination: The N‐iodosuccinimide (NIS)‐catalyzed amidation of acetophenone derivatives by using tert‐butylhydroperoxide (TBHP) as an oxidant is presented. A variety of acetyl derivatives of heterocyclic compounds were easily converted to their corresponding ketoamides under these conditions. A new, NIS‐catalyzed amination of propiophenone and its derivatives in the presence of TBHP to furnish

  单步胺化：介绍了使用叔丁基过氧化氢（TBHP）作为氧化剂的N-碘琥珀酰亚胺（NIS）催化的苯乙酮衍生物酰胺化反应。在这些条件下，杂环化合物的各种乙酰基衍生物很容易转化为它们相应的酮酰胺。在TBHP存在下，一种新的NIS催化的苯乙酮及其衍生物的胺化反应可提供相应的2-氨基酮衍生物，这是首次报道的苯乙酮衍生物的单步胺化反应。
• Therapeutically useful 1-phenyl-2-piperidinoalkanol derivatives
  申请人：Synthelabo

  公开号：US04690931A1

  公开（公告）日：1987-09-01

  Compounds of the formula: ##STR1## wherein R.sub.1 is hydrogen, halogen, trifluoromethyl, alkyl, hydroxyl, alkyoxy, benzyloxy, alkanoyloxy, or benzoyloxy, or when R.sub.2 is hydroxyl or methoxy in the 4-position and R.sub.3 is hydrogen, R.sub.1 may also represent hydroxymethyl carbamoyl or alkoxycarbonyl, R.sub.2 is hydrogen, halogen, alkyl, hydroxyl, or alkoxy, R.sub.3 is hydrogen or alkyl, R.sub.4 is alkyl (in which case the compounds are (.+-.)-erythro) or when R.sub.3 represents hydrogen, R.sub.4 may also be hydrogen, and R.sub.5 is hydrogen, halogen, alkyl, alkoxy, or three methoxy groups in the 3-, 4- and 5-positions and pharmaceutically acceptable acid addition salts thereof, with the exclusion of compounds wherein: (a) one of R.sub.1 and R.sub.2 is in the 4-position and is hydroxyl, alkoxy or benzyloxy, the other is in the 3-position and is hydrogen, hydroxyl, alkoxy or benzyloxy, and R.sub.3 and R.sub.5 are hydrogen and wherein: (b) R.sub.1 is in the 4-position and is halogen, R.sub.4 is methyl and R.sub.2, R.sub.3 and R.sub.5 are hydrogen, are useful as medicaments.

  该化合物的结构式为：##STR1##其中R.sub.1为氢、卤素、三氟甲基、烷基、羟基、烷氧基、苄氧基、烷酰氧基或苯甲酰氧基；或当R.sub.2为4-位的羟基或甲氧基且R.sub.3为氢时，R.sub.1也可以表示羟甲基氨基甲酰或烷氧羰基；R.sub.2为氢、卤素、烷基、羟基或烷氧基；R.sub.3为氢或烷基；R.sub.4为烷基（此时化合物为(.+-.)-erythro）；或当R.sub.3表示氢时，R.sub.4也可以是氢；R.sub.5为氢、卤素、烷基、烷氧基或3-、4-和5-位有三个甲氧基基团的化合物及其药学上可接受的酸盐，排除以下化合物：(a)其中R.sub.1和R.sub.2中的一个位于4-位且为羟基、烷氧基或苄氧基，另一个位于3-位且为氢、羟基、烷氧基或苄氧基，R.sub.3和R.sub.5为氢；以及(b)其中R.sub.1位于4-位且为卤素，R.sub.4为甲基，R.sub.2、R.sub.3和R.sub.5为氢的化合物作为药物是有用的。
• CIRCULATION IMPROVING AGENT
  申请人：GRELAN PHARMACEUTICAL CO., LTD.

  公开号：EP0232423A1

  公开（公告）日：1987-08-19

  A circulation improving agent containing 2-(4-benzyl- piperidino)-1-(4-benzyloxyphenyl)propan-1-ol or a salt thereof as an effective ingredient can be used as a brain circulation improving agent, vasodilator, coronary vasodilator, calcium antagonist, antiplatelet agent, or α1-blocker for prophylaxis, treatment, and improvement of circulatory troubles or diseases.

  含有 2-(4-苄基-哌啶基)-1-(4-苄氧基苯基)丙-1-醇或其盐作为有效成分的循环改善剂可用作脑循环改善剂、血管扩张剂、冠状动脉血管扩张剂、钙拮抗剂、抗血小板剂或α1-受体阻滞剂，用于预防、治疗和改善循环系统疾病。
• KAMETANI TETSUJI; KIGASAWA KAZUO; HIIRAGI MINEHARU; WAGATSUMA NAGATOSHI; +, YAKUGAKU DZASSI, YAKUGAKU ZASSNI, J. PHARM. SOS. JAR., 1980, 100, NO 8, 8+
  作者：KAMETANI TETSUJI、 KIGASAWA KAZUO、 HIIRAGI MINEHARU、 WAGATSUMA NAGATOSHI、 +

  DOI：——

  日期：——
• KEHGASAVA, KADZUO;XIRAGIKI, MINEHDZI;ADZUMA, NAGATOSI;KOXAGISAVA, TOSITAK+
  作者：KEHGASAVA, KADZUO、XIRAGIKI, MINEHDZI、ADZUMA, NAGATOSI、KOXAGISAVA, TOSITAK+

  DOI：——

  日期：——